Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PANK3 | Q9H999 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698288 | 0.92 | L3MBTL1 (0.60) | L3MBTL1PANK3RAB9ACYP1A2PPARG | |
| SCHEMBL6698256 | 0.89 | PANK3 (0.48) | L3MBTL1PANK3RAB9ACYP1A2PPARG | |
| SCHEMBL6702911 | 0.88 | L3MBTL1 (0.48) | L3MBTL1PANK3RAB9ACYP1A2PTPN11 | |
| SCHEMBL7253740 | 0.73 | MT-CO2 (0.55) | L3MBTL1PANK3RAB9APTPN11MT-CO2 | |
| SCHEMBL7253746 | 0.72 | ALDH1A1 (0.45) | PANK3RAB9AMT-CO2NPC1 | |
| SCHEMBL7253800 | 0.72 | ALDH1A1 (0.45) | PANK3RAB9AMT-CO2NPC1 | |
| SCHEMBL7258378 | 0.72 | MAPT (0.54) | RAB9ANPC1 | |
| SCHEMBL14758314 | 0.72 | TRPV4 (0.66) | L3MBTL1RAB9A | |
| SCHEMBL2826663 | 0.72 | PTPN11 (0.54) | L3MBTL1PANK3RAB9ACYP1A2PTPN11 | |
| SCHEMBL7253222 | 0.71 | MAPT (0.51) | L3MBTL1PANK3RAB9APTPN11NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | claimed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | disclosed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | APOB, APOL1, TTR | L3MBTL1 1904/4885PANK3 4777/4885RAB9A 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.